2018 Press Releases
Diabetes drug use during pregnancy linked to child's weight
February 27, 2018
|Contact: Jenni Glenn Gingery
Associate Director, Communications and Media Relations
|Contact: Colleen Williams
Manager, Public Relations
Children born to moms who took metformin face increased risk of obesity
Washington, DC -
When women take the common diabetes medication metformin during pregnancy, it may put their children at increased risk of having obesity or overweight.
A growing number of pregnant women are taking metformin to treat gestational diabetes or a condition called polycystic ovary syndrome (PCOS). PCOS is a common cause of infertility and can put women at risk of developing diabetes and other metabolic health problems. PCOS affects an estimated 7 percent to 10 percent of women of childbearing age, according to the Hormone Health Network.
When pregnant women with PCOS or gestational diabetes take metformin, the medication crosses the placenta and is passed to the fetus.
“Our findings indicate the offspring of women who took metformin for PCOS during pregnancy are more likely to meet the criteria for obesity or overweight than children whose mothers were given a placebo during pregnancy,” said the study’s first author, Liv Guro Engen Hanem, M.D., of the Norwegian University of Science and Technology in Trondheim, Norway. “The results were surprising, since limited past research in this area had suggested metformin would have a protective effect on the children’s metabolic health.”
The researchers invited parents of 292 children who participated in two previous randomized clinical trials to be part of this study. In the previous trials, pregnant women with PCOS were assigned to take either metformin or a placebo during pregnancy. The researchers wound up reviewing body mass index (BMI) and other measurements for 161 children born following the two earlier studies.
At four years of age, the children whose mothers were randomized to metformin during pregnancy tended to weigh more than the children whose mothers took the placebo. Although metformin did not appear to affect birth weight, the trend became apparent when children reached six months of age. At the age of four years, the children in the metformin group had higher BMI scores and were more likely to meet the criteria for obesity or overweight than children in the placebo group.
“Few studies have examined the long-term health of children born to women with PCOS who took metformin,” Hanem said. “Our findings indicate more research is needed to determine its effects on children who were exposed in the womb.”
Other authors of the study include: Solhild Stridsklev, Sven M. Carlsen, Rønnaug Ødegård and Eszter Vanky of the Norwegian University of Science and Technology and St. Olavs Hospital, Trondheim University Hospital, both in Trondheim, Norway; Pétur B. Júlíusson of the University of Bergen in Bergen, Norway; and Mathieu Roelants of KU Leuven – University of Leuven in Belgium.
The research was supported by the Research Council of Norway and NovoNordisk Fonden. Weifa AS supplied metformin free of charge during the two randomized clinical trials.
The study, “Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age; Follow-up of Two RCTs”, will be published online, ahead of print.
Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.
The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.